Free Complaint - District Court of Delaware - Delaware

Case 1:07-cv-00765-SLR

Document 1

Filed 11/27/2007

Page 1 of 10

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE BOSTON SCIENTIFIC CORPORATION and BOSTON SCIENTIFIC SCIMED, INC.,

Plaintiffs,
V.

Civil Action No.

JURY TRIAL DEMANDED

JOHNSON & JOHNSON, INC. and CORDIS CORPORATION,
Defendants.

COMPLAINT FOR DECLARATORY JUDGMENT OF PATENT INVALIDITY AND NONINFRINGEMENT
Plaintiffs Boston Scientific Corporation and Boston Scientific Scimed, Inc, (collectively "BSC"), through their attorneys, bring this complaint against Defendants Johnson & Johnson, Inc. and Cordis Corporation (collectively "J&J") and requests a jury trial on all issues so triable. BSC alleges as follows, upon knowledge with respect to itself and its own acts, and upon information and belief as to the circumstances and facts of others:

NATURE OF THE ACTION
1. This is an action for a declaratory judgment that United States Patent No.

7,300,662 entitled "DrugMrug Delivery Systems for the Prevention and Treatment of Vascular Disease" (the "Falotico '662 patent") is invalid and not infringed by BSC. The Falotico '662 patent is attached as Exhibit A.

DH O l :2484292.1

054604,1003

Case 1:07-cv-00765-SLR

Document 1

Filed 11/27/2007

Page 2 of 10

THE PARTIES
2. Plaintiff Boston Scientific Corporation is a corporation organized under the laws

of the State of Delaware, having its principal place of business at One Boston Scientific Place, Natick, Massachusetts 01760. 3. Plaintiff Boston Scientific Scimed, Inc. is a corporation organized under the laws

of the State of Minnesota, having its principle place of business at One Scimed Place, Maple Grove, Minnesota 55311. 4. Upon information and belief, Defendant Johnson & Johnson, Inc. is a corporation

organized under the laws of the State of New Jersey and has a principal place of business at One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933. 5. Upon infonnation and belief, Defendant Cordis Corporation ("Cordis") is a

corporation organized under the laws of the State of Florida and has a principal place of business in Miami Lakes, Florida. Cordis is a subsidiary of Johnson & Johnson, Inc.

JURISDICTION AND VENUE 6. seq. ). 7. This Court has jurisdiction over the subject matter of all causes of action herein This action arises under the Patent Laws of the United States (35 U.S.C. § 1, et

pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201 and 2202. 8. On information and belief, J&J has systematic and continuous contacts in this

judicial district. 9. On information and belief, J&J regularly avails itself of the benefits of this

judicial district, including the jurisdiction of the courts.

2 DB01:2484292. [ 054601.1003

Case 1:07-cv-00765-SLR

Document 1

Filed 11/27/2007

Page 3 of 10

10. district. 11.

On information and belief, J&J regularly transacts business within this judicial

On information and belief, J&J regularly sells products in this judicial district.

J&J derives substantial revenues from sales in this district. 12. 13. and 1400(b). This Court has personal jurisdiction, general and specific, over J&J. Venue in this judicial district is proper pursuant to 28 U.S.C. §§ 1391(b) and (c)

BACKGROUND 14. BSC is a world renowned leader in the development of intravascular stents used

to treat coronary artery disease. 15. J&J and, in particular, Cordis, directly compete with BSC in the field of

intravascular stents used to treat coronary artery disease. 16. J&J has a well-known history of suing competitors, including BSC, in the field of

intravascular stents for patent infringement. Within the past several years, J&J and/or Cordis have sued BSC in this Court, alleging patent infringement in cases involving intravascular stents used to treat coronary artery disease. BSC has also brought suits for patent infringement against J&J within this judicial district. 17. Pursuant to an agreement between BSC and Abbott Laboratories ("Abbott"), BSC

is presently selling the PROMUSTM Everolimus-Eluting Coronary Stent System ("PROMUS") in Europe and other countries outside the United States. The PROMUS stent is a private-labeled XIENCETM V Everolimus Eluting Coronary Stent System ("XIENCE V") which is manufactured for BSC by Abbott in the United States. The PROMUS stent is an intravascular stent used to

3
DBOJ :248292.1 054604.1003

Case 1:07-cv-00765-SLR

Document 1

Filed 11/27/2007

Page 4 of 10

treat coronary artery disease. It advantageously releases a drug designed to diminish reblocking (restenosis) of the patient's blood vessel into which the stent has been inserted. 18. The PROWS stent received CE Mark approval in October 2006, which allows

BSC to distribute PROWS in 27 countries of the European Economic Area. Since that time, BSC has been taking title to the PROWS stent from Abbott in the United States and then exporting those stents to the European market. BSC intends to begin selling its PROWS stent in the United States in 2008. 19. In 2006, BSC purchased Guidant Corporation ("Guidant"). As part of the

agreement governing the Guidant acquisition, Guidant separately sold the rights to its everolimus-eluting scent product to Abbott. BSC separately entered into an agreement with Abbott that permits BSC to sell (under the designation "PROMUS") the everolimus-eluting stents manufactured by Abbott (which Abbott sells on its own as its "XIENCE V" stent). 20. Abbott currently manufactures and sells its own everolimus-eluting stent, the

XIENCE V stent, which is the same product as BSC's PROWS stent, and BSC has made a substantial investment in the PROMUS stent. 21. On May 15, 2007, Cordis filed a Complaint against Abbott in the United States

District Court for the District of New Jersey (Civil Action No. 07-2265), alleging infringement of U.S. Patent No. 7,217,286 (the "Falotico '286 patent" or alternatively, the "'7286 patent"). On May 29, 2007, Cordis filed a Complaint against Abbott in the United States District Court for the District of New Jersey (Civil Action No. 07-2477), alleging infringement of U.S. Patent No. 7,223,286 (the "Wright '286 patent" or alternatively, the "'3286 patent"). On June 12, 2007, Cordis filed a Complaint against Abbott in the United States District Court for the District of New Jersey (Civil Action No. 07-2728), alleging infringement of U.S. Patent No. 7,229,473 (the

4 RB01:2484292 . I 054604.1003

Case 1:07-cv-00765-SLR

Document 1

Filed 11/27/2007

Page 5 of 10

"Wright '473 patent"). Collectively, these three Cordis patents are referred to as "the Asserted Cordis Patents." 22. During the prosecution of each of the Asserted Cordis Patents, Cordis separately

petitioned the United States Patent and Trademark. Office for expedited consideration in view of perceived patent infringement in connection with the XIENCE V stent. Upon issuance of these three patents, Cordis promptly asserted the new patents against Abbott. Exactly the same circumstances exist with regard to the Falotico '662 patent: Cordis likewise petitioned for expedited Patent Office review of the application that led to the Falotico '662 patent based, again, on perceived infringement by the XIENCE V stent. The petition of August 7, 2006 is attached as Exhibit B. 23. Cordis' recent pattern of promptly asserting its new patents, and in particular

those patents issuing from an expedited Patent Office evaluation demanded by Cordis because of alleged infringement, has created a present substantial controversy between J&J and BSC concerning the PROMUS stent. J&J, through Cordis, has asserted rights under related patents against the same product as the PROMUS stent, and the alleged infringement of the Asserted Cordis Patents has created an apprehension that Cordis will sue BSC for alleged infringement of the Falotico '662 patent.

RELATED CASES PENDING IN THE DISTRICT OF DELAWARE
24. There are now five cases pending in the District of Delaware that are related to

the instant case, as set forth in the below paragraphs.

25.

On September 29, 2006, Abbott filed a declaratory judgment action against J&J,

alleging that other Cordis-awned patents - U.S. Patent Nos. 6,585,764 (the `764 patent"), 6,776,796 (the "'796 patent"), and 6,808,536 (the "'536 patent") - are invalid and not infringed

5
DB01:24842921 054504.1003

Case 1:07-cv-00765-SLR

Document 1

Filed 11/27/2007

Page 6 of 10

by Abbott's manufacture and/or use of the XIENCE V stent in the Unites States. (See Ex. C, the complaint in Civil Action No. 06-613-SLR).' Although on August 8, 2007, Cordis granted Abbott a covenant not to sue on those patents, that action remains active in view of pending motions to amend the complaint, as explained below. 26. On May 15, 2007, Abbott filed a declaratory judgment action against Cordis in

the United States District Court for the District of Delaware relating to U.S. Patent No. 7,217,286 (the "Falotico '286 patent"). (See Ex. D, the complaint in Civil Action No. 07-259-SLR). Abbott alleges in its May 15 complaint that the Falotico '286 patent is invalid and not infringed by Abbott's manufacture and/or use of the XIENCE V stent in the Unites States. (Id, at p. 17). Abbott's declaratory judgment action against the Falotico '286 patent, which is currently pending in this judicial district, is the first filed action concerning the Falotico '286 patent. Also on May 15, 2007, Abbott filed a motion for leave to file a supplemental complaint or in the alternative to consolidate related cases in Civil Action No. 06-613-SLR pending before the United States District Court for the District of Delaware. (See Ex. E, Abbott's motion for leave to file a supplemental complaint or consolidate related cases). Abbott's motion requests leave to file a supplemental complaint to add a claim for declaratory judgment of invalidity and noninfringement of the Falotico '286 patent. (Id. at p. 2). 27. On May 25, 2007, BSC filed a declaratory judgment action against Cordis in the

United States District Court for the District of Delaware relating to the Falotico '286 patent. (See Ex. F, the complaint in Civil Action No. 07-333-SLR). BSC asserts in that May 25

' The exhibits originally filed with Exhibits C-L herein have not been attached. Exhibits C-K correspond to Exhibits C-K filed with the compliant in Civil Action No. 07-409-SLR and Exhibit L is the complaint in Civil Action No. 07-409-SLR. Should the Court require a copy of these exhibits, Plaintiffs are available to do so.

6
DB01:2484292.1 054604.1003

Case 1:07-cv-00765-SLR

Document 1

Filed 11/27/2007

Page 7 of 10

complaint that the Falotico '286 patent is invalid and not infringed by BBC's above-recited activities regarding the PROMUS stent. (Id. at p. 6). 28. On May 29, 2007, Abbott filed a supplemental motion for leave to file a

supplemental complaint or in the alternative to consolidate related cases in Civil Action No. 06613-SLR pending before the United States District Court for the District of Delaware. (See Ex. G, Abbott's motion for leave to file a supplemental complaint or to consolidate related cases). Also on May 29, 2007, Abbott filed a motion for leave to file a supplemental complaint in Civil Action No. 07-259-SLR pending before the United States District Court for the District of Delaware. (See Ex. H, Abbott's supplemental motion for leave to file a supplemental complaint). Abbott's motions request leave to file supplemental complaints to add claims for declaratory judgment of invalidity and noninfringement of U.S. Patent No. 7,223,286 (the "Wright '286 patent"). (Ex. G at p. 1; Ex. H at p. 1). 29. On June 1, 2007, BSC filed a declaratory judgment action against J&J in the

United States District Court for the District of Delaware relating to the Wright '286 patent. (See Ex. 1, the complaint in Civil Action No. 07-348-SLR). BSC asserts in its Tune 1 complaint that the Wright '286 patent is invalid and not infringed by BBC's above-recited activities regarding the PROMUS scent. (Id. at p. 7). 30. On June 12, 2007, Abbott filed a second supplemental motion for leave to file a

supplemental complaint or in the alternative to consolidate related cases in Civil Action No. 06613-SLR pending before the United States District Court for the District of Delaware. (See Ex. J, Abbott's second supplemental motion for leave to file a supplemental complaint or to consolidate related cases). Also on June 12, 2007, Abbott filed a supplemental motion for leave to file a supplemental complaint in Civil Action No. 07-259-SLR pending before the United

7 DBO 1:2484292 . 1 034604.1043

Case 1:07-cv-00765-SLR

Document 1

Filed 11/27/2007

Page 8 of 10

States District Court for the District of Delaware. (See Ex. K, Abbott's supplemental motion for leave to file a supplemental complaint). Abbott's motions request leave to file supplemental complaints to add claims of invalidity and noninfringement of U.S. Patent No. 7,229,473 (identified as the "Wright '473 patent"). (Ex. J at p. 1; Ex. K at p. 1). 31. On June 22, 2007, BSC filed a declaratory judgment action against J&J in the

United States District Court for the District of Delaware relating to the Wright '473 patent. (See Ex. L, the complaint in Civil Action No. 07-409-SLR). BSC asserts in its June 22 complaint that the Wright '473 patent is invalid and not infringed by BSC's above-recited activities regarding the PROMUS stent. (Id. at p. 8). 32. The instant action by BSC against J&J is related to Abbott's September 29, 2006

action because at least the Falotico '796 patent is part of the same patent family as the Falotico '662 patent, the prior art to both patents is related, and the products at issue in the September 29, 2006 action (Abbott's XIENCE V) and this action (BSC's PROMUS) are related. Also, as discussed above, Abbott has also recently filed motions to amend its complaint in the September 29, 2006 action to include the Falotico '286 patent, the Wright '286 patent, and the Wright '473 patent or, in the alternative, consolidate its September 29, 2006, May 15, May 29, and June 12 actions. 33. The instant action by BSC against J&J is related to Abbott's May 15 complaint

and supplemental complaint and BSC's May 25 complaint on the Falotico '286 patent, Abbott's May 29 supplemental complaints and BSC's June 1 complaint on the Wright '286 patent, and BSC's June 22 complaint on the Wright '473 patent, because the patents involved all have claims purporting to cover similar subject matter, the prior art to the those patents is related, and the products of the declaratory judgment plaintiffs, XIENCE V (Abbott) and PROMUS (BSC), are

8
DB01:2484242.1 054604.1003

Case 1:07-cv-00765-SLR

Document 1

Filed 11/27/2007

Page 9 of 10

related . Essentially identical Scheduling Orders have been entered in Abbott's declaratory judgment case (Civil Action No. 06-613-SLR, D.I. 85) and BSC' s declaratory j udgment cases (Civil Action No. 07-333-SLR, D.I. 19; Civil Action No. 07-348-SLR, D.I. 17; Civil Action No. 07-409-SLR, D.I. 18).

COUNTI INVALIDITY AND NONINFRINGEMENT OF U.S. PATENT NO.7 ,300,662
34. BSC repeats and realleges each and every allegation contained in paragraphs 1-33

of this Complaint as though fully set forth herein. 35. Each of the claims in the Falotico '662 patent is invalid for failure to comply with

one or more of the requirements of Title 35, United States Code, including, but not limited to, 35 U.S.C. §§ 102,103 and 112. 36. The PROMUS stent does not infringe any valid claim of the Falotico '662 patent.

PRAYER FOR RELIEF
WHEREFORE, BSC prays that this Court enter judgment as follows, ordering that: (a) (b) Each and every claim of U.S. Patent No. 7,300,662 is invalid; Plaintiffs are not liable for directly, contributorily or inducing infringement of any

claim ofU.S. Patent No. 7,300,662; (c) Defendants and their officers, agents, employees, representatives, counsel and all

persons in active concert or participation with any of them, directly or indirectly, be enjoined from threatening or charging infringement of, or instituting any action for infringement of U.S. Patent No. 7,300,662 against Plaintiffs, its suppliers, customers, distributors or users of its products;

9
DB01:2484242.1 054604,1003

Case 1:07-cv-00765-SLR

Document 1

Filed 11/27/2007

Page 10 of 10

(d)

Defendants pay to Plaintiffs the costs and reasonable attorney's fees incurred by

Plaintiffs in this action; and (e) ,proper, Plaintiffs be granted such other and further relief as this Court deems just and

DEMAND FOR JURY TRIAL
Plaintiffs demand a trial by jury on all issues so triable.

YOUNG CONAWAY STARGATT & TAYLOR, LLP

Josy W. Ingersoll (##1088 Karen E. Keller (44489) The Brandywine Building, 17`1' Floor 1000 West Street Wilmington, DE 19801 jingersoll @ycst.com [email protected] (302) 571-6554

Of Counsel: Richard L. Delucia Paul M. Richter Michael K. Levy Jerry Canada

Attorneys for Plaintiffs Boston Scientific Corgioration and Boston Scientific Schned, Inc.

KENYON & KENYON LLP One Broadway New York, NY 10004 (212) 425-7200

Dated : November 27, 2007

DB0 1 :2484292.1

10
054504.1003

Case 1:07-cv-00765-SLR

Document 1-2

Filed 11/27/2007

Page 1 of 25

EXHIBIT A

Case 1:07-cv-00765-SLR

Document 1-2
IN

Filed 11/27/2007

Page 2 of 25

I I I I 1 1 1 1 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 IN 1 11 IN
(la) Patent No.: US 7,300,662 B2 (45) Date of Patent : 'Nov. 27, 2007
Field of Classification Search ........ 4241422-426; 623/1.42-1.48 See application file for complete search history. References Cited U.S. PATENT DOCUMENTS
861,659 A 3,051,677 A 3,279,996 A 3,526,005 A 3,599,641 A 711907 81962 10,11966 911970 811971 Johnston .... ................. 464/147 Rexford ...................... 522,'l 56 Long et al . ................ 424;424 Bokros . ................... 623111.11 Sheridan ..................... 6041256

(12) United States Patent
Falotico et al.
(54) DRUGIDRUG DELIVERY SYSTEMS FOR THE PREVENTION AND TREATMENT OF VASCULAR DISEASE Inventors. Robert Falotico, Belle Mead, NJ (US); Gregory A. Kopin, Hillsborough, NJ (US); Gerard H. Lianos, Stewartsville, NJ (U5) Assignee: Gordis Corporation , Miami Lakes, FL (US) Subject to any disclaimer, the temt of this patent is extended or adjusted under 35 U.S.C. 154(b) by 503 days. This patent is subject to a terminal disclaimer. (21) (22) (65) Appl. No.: 101829,074 Filed: Apr. 21, 2004 Prior Publication Data US 200410260268 Al Dec. 23, 2004

(58)

(75)

(56)

(73)

{) Notice :

(Continued) FOREIGN PATENT DOCUMENTS
DE 3205942 AI 911983

(Continued) OTHER PUBLICATIONS
Boston Scientific , ";Measuring DES Efficacy," WW%v.xxus-stcnt. comousaMiptcacy . htmi, pp. 1-3, copyright 2006.·

Related U.S. Application Data (63) Continuation-in-part of application No. 091850,293, filed on May 7, 2001, now abandoned, which is a continuation-in-part of application No. 091575,480, filed on May 19, 2000. Provisional application No. 601263,979, filed on Jan. 25, 2001, provisional application No. 601263,806, filed on Jan. 24, 2001, provisional application No, 601262,614, filed on Jan. 18, 2001, provisional application No. 60/262,461, filed on Jan. 18, 2001, provisional application No. 60/204,417, filed on May 12, 2000. Int. Cl. (2006.01) A61F 2100 (2006.01) A61F 2106 U.S. CI ...................... 4241424; 623/1.42; 62311.45

(Continued) Primmy %varniner---Sharon E. Kennedy
(74) Attorney, Agent, or Firm--Woodcock Washburn LLP

(57)

ABSTRACT

(60)

(51)

A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointinial hyperplasia following percutancous transluminaI coronary ongiography. The local delivery of the drugs or agents provides for increased efibctiveness and lower systemic toxicity. 25 Claims, 2 Drawing Sheets

(52)

104

Case 1:07-cv-00765-SLR

Document 1-2

Filed 11/27/2007

Page 3 of 25

US 7,300,662 B2
Page 2 U.S. PATENT DOCUMENTS
3,657,744 A 3,744,596 A 3,779,805 A 3,929,992 A 3,932,627 A 3,948,254 A 3,952,334 A 3,968,800 A 4,069,307 A 4,076,285 A 4,292,965 A 4,299,226 A 4,300,244 A 4,312,920 A 4,321,711 A 4,323,071 A 4,390,599 A 4,413,359 A 4,423,183 A 4,441,216 A 4,503,569 A 4,512,338 A 4,550,447 A 4,553,545 A 4,560,374 A 4,562,596 A 4,565,740 A 4,580,568 A 4,613,665 A 4,642,111 A 4,655,771 A 4,656,083 A 4,676,241 A 4,678,466 A 4,687,482 A 4,689,046 A 4,731,054 A 4,733,665 A 4,739,762 A 4,740,207 A 4,749,585 A 4,753,652 A 4,760,849 A 4,768,507 A 4,776,337 A 4,786,500 A 4,787,899 A 4,800,882 A 4,810,784 A 4,856,516 A 4,871,357 A 4,872,867 A 4,876,109 A 4,886,062 A 4,907,336 A 4,916,193 A 4,954,126 A 4,969,458 A 4,990,131 A 4,990,155 A 4,994,071 A 4094,298 A 4,998,923 A 5,015,253 A 5,019,090 A 5,019,096 A 5,029,877 A 5,034,265 A 5,035,706 A 5,041,100 A 5,041,126 A 411972 7/1973 12,11973 12/1975 1/1976 411976 4!1976 711976 111978 211978 10( 1981 1111981 1111981 111982 311982 4!1982 6!1983 1111983 1211983 4! 1984 311985 4! 1985 11/1985 1111985 1211985 111986 U1986 4?1986 9? 1986 2/1987 411987 411987 6/1987 711987 81 1987 811987 311988 3?1988 4!1988 4!1988 6?1988 6!1988 9/ 1988 911988 10?1988 1111988 11/1988 111989 3/1989 81 1989 10/ 1989 10/1989 101989 1211989 311990 4!1990 911990 11/1990 211991 211991 2! 1991 211991 3! 1991 511991 511991 5!1991 711991 711991 7/1991 8/ 1991 8! 1991 Ersck Sandcr ....................... 188/203 Alsbcrg ...................... 4271105 Schgal ct al ................ 4241122 Margraf 7ai3'aroni .................... 1281833 Bokros et al. ........... 623111.11 Vilasi ......................... 6061198 Higuchi et al . ............. 4241432 Martin4z .................... 285,332 Nash ct al. Banks ........................ 6041509 Bokras ...................... 62311.13 Pierce et al .............. 4281425.5 Mano ......... ............... 623/1.43 Simpson et al . ............ 6061194 Broyles ......................4281597 Akiyama et al. ........ 623123.72 Close ......................... 5241546 lonescu et al. Dotter Balko et al. ........ 6061108 Seiler, Jr. ct al........... 62311.32 Maass et al. Hammcrslag ............... 6041509 Kronberg ................... 62311.32 Golandcr et al. ........... 4281409 Gianturco /arm Sakamoto ct al. .......... 424,492 Wallsten Hoffman ct al ............. 4421123 1281207.14 Webb et al. Rosenwald . ................ 4241427 Hanson ..................... 62311.49 Bokros ...................... 62312.31 Billctcr ct al . ........,.. 604193.01 5,047,020 A 5 ,049 , 132 A 5,049,403 A 5,053,048 A 5,059,66 A 5,061,275 A 5,061,750 A
5,1)64,435 A

9/1991 911991 911991 10/199 1011991 1011991 1011991

Palutaz
Pal maz Krcarncr .................... 62311.15

Greco et al ................. 428.'422
Langer ct al . ............. 62311.42 hropf . ........................ 606?191 Fischell ct al . ............ 623/1.11 Palanaz Wang ......................... 4241422 Lazarus ..................... 62311.11 Gianturco Larm .......................... 536,20 Hillstcad Hsu et al .................... 6041266 Joh Mayer ct al. ............... 6041269 Wiktor Gianturco Tang et al. Wallsten Wiktor Dardik

Wilkoff
MacGregor Yasuda ....................... 427,490 Samson et al . ............. 6061194 MacGregor Pinchuk ..................... 62311.15 Fox, Jr. ct al. ............... 600,36 Fedeli ct al. - ......... -. 2771354 Hoffman et al ............. 442,1126 Gianturco Rowl..md ct al. Gianturco

5,092,877 A 5,102,417 A 5,104,404 A 5,116,365 A 5,122,154 A 5,131,908 A 5,133,732 A 5,134,192 A 5,135,536 A 5,163,952 A 5,163,958 A 5,171,217 A 5,171,262 A 5,176,660 A 5,176,972 A 5,178,618 A 5,180,366 A 5,182,317 A 5,185,408 A 5,192,307 A 5,195,984 A 5,202,332 A 5,213,576 A 5,23,898 A 5,217,483 A 5,222,971 A 5,226,913 A 5,234,456 A 5,246,445 A 5,258,020 A 5,258 ,021 A 5,262,451 A 5,266,073 A 5,272,012 A 4,733,665 A 5,275,622 A 5,282,823 A 5,282,824 A 5,283,257 A 5,288,711 A 5,290,305 A 5,292,331 A 5,292,802 A 5,304,121 A 5,304,200 A 5,306,250 A 5,308,862 A 5,308,889 A 5,314,444 A 5,314,472 A 5,328,471 A 5,334,301 A 5,336,518 A 5,338,770 A 5,342,348 A 5,342,387 A 5,342,621 A 5,354,257 A 5,354,308 A 5,356,433 A 5,366,504 A 5,368 ,566 A 5,370,683 A 5,370,691 A 5,375, 612 A

Hsu ........................... 604/266 Sh a lTer et at Larm et al ................... 42712.1 Pinchuk Fischelt el al . ................ 60013 Wallsten et al. Feijen et al. 1111991 Porter 311992 Pinchuk 411992 Palmaz 411992 Wolff 511992 Hillstead 611992 Rhodes 7/1992 Dardik et al. 711992 Wiktor 711992 Fcijen et al. 811992 Hillstead 11/1992 Froix 1111992 Pinchuk 12/1992 March ct al . ............... 6041507 12` 1992 MacGregor 1.'1993 Tntckai 111993 Bloom ct al , ................. 430114 111993 liandapa 1/1993 Woods 111993 Winters et al. 211993 Tang et al. 311993 Wall 311993 Schalz 411993 Ilughes et al. .............. 5141291 511993 Abiuso et al. 5/1993 Larm et al .................. 4281422 6/1993 Tower 6!1993 Willard et al. 7/1993 Pinchuk 811993 Silvestrini 9/1993 Yachin ct al. 1111993 Froix 1111993 Duna( I tl1993 Winters et al. 11,993 Wall 1211993 Opolski ................... 428;4231 111994 Palmaz ....................... 6061108 111994 Lazarus ct al. 11994 Schwartz et al. 211994 Gianturco 211994 Gregory et al. 21994 Mitchell et al. 311994 Inoue 3/1994 Aoneau 311994 Rhee ct al. 411994 Sahatjian 411994 Spaulding 4/1994 Match et al. 511994 Ohlstein 511994 Rhee ct al. 511994 Gianturco 511994 Fontaine 711994 Slcpian 811994 Heinkc ct al. 811994 Pallassana et al. 8/1994 Winters et al. 811994 Kaplan 8!1994 Summers 8/1994 Eury 1011994 Roubin et al. 10,11994 Simon et al. 1011994 Rowland et al. 11/1994 Andersen et al. 11/1994 Crocker 1,'1994 Fontaine 121994 Samson 1/1994 Cottenceau ct al.

Case 1:07-cv-00765-SLR

Document 1-2

Filed 11/27/2007

Page 4 of 25

US 7,300,662 B2
Page 3
5,376,112 A 5,378,475 A 5,380,299 A 5,382,261 A 5,383,853 A 5,383,928 A 5,387,235 A 5,389,106 A 5,391,730 A 5,393,772 A 5,395,390 A 5,397,355 A 5,399,352 A 5,403,341 A 5,405,377 A 5,409,696 A 5,411,549 A 5,415,619 A 5,417,969 A 5,419,760 A D359,802 S 5;121,955 A 5,423,885 A 5,429,618 A 5,429,634 A 5,439,446 A 5,441,515 A 5,441,516 A 5,441,947 A 5,443,458 A 5,443,477 A 5,443,496 A 5,443,498 A 5,443,500 A 5,447,724 A 5,449,372 A 5,449,373 A 5,449.382 A 5,464,450 A 5,464,540 A 5,464,650 A 5,474,563 A 5,486,357 A 5,496,365 A 5,500,013 A 5,504,091 A 5,510,077 A 5,512,055 A 5,516,781 A 5,519,042 A 5,523,092 A 5,527,354 A 5,545,208 A 5,551,954 A 5,554,182 A 5,554,954 A 5,556,413 A 5,559,122 A 5,562,922 A 5,563,146 A 5,569,197 A 5,569,295 A 5,569,462 A 5,569,463 A 5,571,089 A 5,571,166 A 5,574,059 A 5,575,818 A 5,578,075 A 5,580,873 A 5,580,874 A 5,591,140 A 5,591,197 A 1211994 Duran 111995 Smith at al ................. 424/473 111995 Fimmot ct al. 111995 Patrnaaz 1/1995 Jung, el at .............. 6041103.04 1!1995 Scott ct al. 211995 Chuter 211995 Tower 211995 Skotnicki at al. ........... 5401456 211995 Yoe et al. 311995 Simon at al. 311995 Mann et al. 311995 Hanson ......................4241423 4/1995 Solar 41995 Crngg 411995 Narayanan at al. 511995 Peters 511995 Lee at it. 511995 Hsu at al ................. 424/7Q7 511995 Nlarciso, Jr. W1995 Fontaine 6.'1995 Lau 611995 Williams 7/1995 Keogh 711995 Narciso 811995 Barry 8.!1995 Khosravi at al. 811995 Wang el al. 811995 Dodge et al. 811995 Eury 811995 Maria at .d. &11995 Schwartz at al. 8!1995 Fontaine 811995 Sigwart 911995 Heimus at al. 9/1995 Schmaltz ct at. 9!1995 Pinchasik at al. 911995 Dayton 1111995 Busccmi at al. 1111995 Friesen at al. .............. 210,640 1111995 Berg at al. 1211995 Myler et al. ................ 606!108 1/1996 Narayanan 311996 Sgro 311996 Busccmi at ,d. 41996 Molnar-Kimbcr at al. .. 5141291 4/1996 Dinh at it. 411996 Domb at al ................. 604/265 511996 Morris ct al. 511996 Morris et al ................ 5141378 611996 Hanson at al. 6!1996 Fontaine cc al. 8!1996 WolITal al. 911996 Busccmi at al. 911996 Dinh ct at. 911996 Takahashi 911996 L..= 9?1996 Nelson ct al . .............. 5141291 10?1996 Lambert 10!1996 Morris at al. 1011996 Helmus at al. 1011996 Lain 1011996 Martinson ct al.....,..... 4241423 10!1996 Helmus et al . ............. 424/426 1111996 Crocker ................. 604./103.01 1111996 Dinh at nt. 11/1996) Regunathan at al. 1111996 Pinchuk ..................... 62311.15 1111996 Dayton 1211996 Bianco ct al, 1211996 Bianco et al. U1997 Narayanan at al. 111997 Orth et al, 5,591,224 A 5,591,227 A 5,599,352 A 5,603,722 A 5,604,283 A 5,605,696 A 5,607,463 A 5,607,475 A 5,609,629 A 5,616,608 A 5,620,984 A 5,621,102 A 5,622,975 A 5,624,411 A 5,628,785 A 5,629,077 A 5.629,315 A 5,632,763 A 5,632,771 A 5,632,776 A 5,632,840 A 5,635.201 A 5,637,113 A 5,643,312 A 5,643,939 A 5,646,160 A 5,648,357 A 5,649,952 A 5,649,977 A 5,651,174 A 5,652,243 A 5,653,747 A 5,653,992 A 5,662,609 A 5,665,591 A 5,665,728 A 5,667,764 A 5,669,924 A 5,670,506 A 5,672,638 A 5,674.242 A 5,679,400 A 5,679,659 A 5,684,061 A 5,691,311 A 5,693,085 A 5,697,967 A 5,697,971 A 5,700,286 A 5,707,385 A 5,709,874 A 5,713,949 A 5,716,981 A 5,725,549 A 5,725,567 A 5,728,150 A 5,728,420 A 5,731,326 A 5,733,327 A 5,733,920 A 5,733,925 A 5,735,897 A 5,739,138 A 5,755,734 A 5,755,772 A 5,759,205 A 5,769,883 A 5,776,184 A 5,780,462 A 5,780,476 A 5,782,908 A 5,788,979 A 5,792,106 A 111997 Schwartz ct it. 111997 Dinh et al. 211997 Dinh at al. 211997 Phan at al. 2!1997 Wada et al. ................ 5241236 211997 Fury at al. 311997 Schwartz at al. 311997 Cahalan cl it. 311997 Fearnot at al. 411997 Kinsella et al. ............. 514,449 411997 Bianco al al. 411997 Bianco ut al. 4'1997 Singh at it. 4'1997 Tuch 511997 Schwartz at al. 511997 Turniund at al. 511997 Bianco et it. 511997 Glastra 511997 Boatrnan at al..........., 62311.15 511997 Kurumalani al al......... 424;423 511997 Campbell 611997 Fabo .......................... 424!443 611997 Tartaglia el al. 711997 Fischell at al. 711997 Ohlstein 711997 Morris at al. 711997 Bianco et .it. 711997 Lam 711997 Campbell 711997 Schwartz at al, 711997 Blanco at at. 811997 Dercumc ................... 62311.54 811997 Bezw:ada at al, 911997 Slepian 9/1997 Soncnshein at at. ........ 4351375 911997 Morris et al. 911997 Kopia ct al ................ 42411.45 911997 Shaknovieb 9`1997 Leigh ct al. 9'1997 Vcrhoevcn at al. ......... 5231112 1011997 Phan al al . ................. 606198 1011997 Tuch 1011997 Vcrhoeven et al. 1111997 Ohnishi at al . ............. 523;114 1111997 M.uagarore at al. ......... 514112 1211997 Buige et al. IV1997 Dinh at al. 12!1997 Fischell at al. 12/1997 Tartaglia at ,it. 1/1998 Willlams 111998 Hanson at al. 2/1998 Jayaraman ................. 62311.12 2/1998 Hunter at at ................ 5141449 311998 Lam 311998 Wolff et al. 311998 McDonald at at. 311998 Keogh 311998 Hart at al. 311998 Igaki et at. 3/1998 Mansuri at al. 311998 Kunz at al. 411998 Buirge 4,' 1998 Bianco at al. 511998 Richter ct al. 5/1998 Evans ct it. ................ 1281898 611998 Valcntini .................... 4331173 611998 Busccmi et al. 7/1998 "much 711998 Lee et al . ................... 5141183 711998 Underiner at al. 711998 Cahalan et al. 811998 Alt 811998 Mische .................. 6041103.01

Case 1:07-cv-00765-SLR

Document 1-2

Filed 11/27/2007

Page 5 of 25

US 7,300,662 S2
Page 4
5,792,772 A 5,798,372 A 5,799,384 A 5,800,507 A 5,800,508 A 5,807,861 A 5,811,447 A 5,820,917 A 5,820,918 A 5,824,048 A 5,824,049 A 5,827,587 A 5,833,651 A 5,837,008 A 5,837,313 A 5,843,120 A 5,843,166 A 5,843 ,172 A 5,849,034 5,851,217 5,851,231 5,858,990 5,861,027 5,865,811 5,871,535 5,873,904 5,876,433 5,877,224 5,879,697 5,882,335 5,891,108 5,893,840 5,897,911 5,900,246 5,902,266 5,912,253 5,916,910 5,922,393 5,922,730 A 5,932,243 A 5,932,299 A 5,932,580 A 5,951,586 A 5,957,971 A 5,968,091 A 5,972,027 A 5,976,534 A 5,977,163 A 5,980,553 A 5,980,566 A 5,980,972 A 5,981,568 A 5,985,307 A 5,997,468 A 6,004,346 A 6,015,432 A 6,015,815 A 6,039,721 A 6,059,813 A 6,071,305 A 6,074,659 A 6,080,190 A 6,096,070 A 6,120,536 A 6,120,847 A 6,136,798 A 6,140,127 A 6,146,358 A 6,153,252 A 6,159,488 A 6,171,232 BI 6,171,609 B1 6,177,272 Bt 811998 Bianco al at. 811998 Davies at al. 911998 Schwartz ct al. 911998 Schwartz 9?1998 Goicocchea ct al. 9?1998 Klein et al. 911998 Kunz at at. 1011998 Tuch 1011998 Ronan et al. 10?1998 Tuch 1011998 Ragheb at at. 1011998 Fukushi ..................... 428136.6 1111998 Donovan el it, 1111998 Berg at al, 1111998 Ding et at. 1211998 Israel eta] ................. 623.11.15 12/1998 Lentz et al. ............... 623/1.13 1211998 Yan 1711998 Schwartz 12,11998 Wolff ct al. I711998 Wolf at at. 111999 Walsh 1! 1999 Trapp 2!1999 Tuch 211999 Wotfl et al. 211999 Ragheb et it, 311999 Lunn 311999 Brocchini ct at. ....... 5141772.2 311999 Ding ct al. 3.11999 Leone et al. 411999 Leone et al. 411999 Hull ct al . ............. 6041103.02 411999 Locmcr ..................... 42712 25 511999 T a:nbert 511999 Leone et at. 611999 Cottens et al ............... 5141291 611999 Lai ............................ 5141423 711999 Jayanunan .................. 427,2.3 711999 Hu ct at . .................... 514,291 811999 Fricker et a . .............. 4241450 811999 Katool .......................4271508 811999 Levitzki at at .............. 1811152 911999 Berg at at. 911999 Schwartz 1011999 Pinchuk et al ............. 62311.16 10!1999 Johnson 1111999 Hart et at. 1111999 Li at at, 1111999 Gray et al. 1111999 Alt at al. 1111999 Ding 1111999 Kunz et al. 1111999 Hanson at al. 1211999 IVolff ct al. 1211999 Wolf et ,It. 1/2000 Rakos et al ................ 6231133 112000 Mollison .................... 514/291 312000 Johnson ct al. 512000 Vrba ct al. 612000 Brown at al. 61200U Kunz et al. 612000 Schwartz 8!2000 Ragheb at al. 9/2000 Dings at al. WNW Yang cl ,it . ................. 4271335 1012000 Cody et al. 1412000 Sprague 1112000 Rowe 1112000 Hossainy at at. 12/2000 Nagier at al, .- ........... 4241423 1/2001 Papandreou et al. 1/2001 Kunz. 112001 Nabcl at al. 6,179,817 BI 6,87,757 BI 6,193,746 BI 6,214,901 B1 6,225,346 B1 6,240,616 BI 6,245,537 B1 6,251,920 131 6,254,632 B 6,254,634 B1 6,258,12 B1 6,268,390 BI 6,273,913 BI 6,284,305 131 6,287,320 B 6,287,628 B1 6,299,604 BI 6,306,144 BI 6,306,166 BI 6,306,176 BI 6,306,421 BI 6,309,380 B1 6,309,660 131 6,313,264 B1 6,316,018 B l 6,335,029 BI 6,358,556 131 6,369,039 BI 6,379,382 BI 6,387,121 BI 6,403,635 BI 6,407,067 BI 6,517,858 BI 6,517,889 BI 6,545,097 B2 6,585,764 B2 6,620,194 B2 6,746,773 B2 61,776,796 B2 6,808,536 B2 200110007083 Al 2001,0029351 Al 2001/0029660 Al 200110032014 Al 2001/0034363 Al 200110037145 Al 2002.10010418 Al 2002!0032477 Al 2 0 0 2100 4 1 899 Al 2002/0061326 Al 200?10068969 Al 200210071902 Al 200210082680 AI 2002!0082685 A 1 2002/0091433 AI 200210095114 A I 200210099438 A l 2002ID103526 Al 200210119178 A 1 20 0 210 1 23 5 05 Al 200210127327 Al 200210133222 Al 200210133224 AI 2002/0165608 Al 200210193475 A 1 200310065377 A 1 2003/0216699 A 1 2004!0049265 A 1 200410243097 A 1 2004?0260268 Al 200510002986 Al 200510004663 Al 2005/0033261 AI 1/2001 Zhong ........................ 6041265 2%2001 Clackson et al . ............. 514131 2+2001 Strecker .................... 62311.13 412001 Chudzik at al. 512001 Tang et al. ................. 5141523 612001 Yon 612001 Williams et al ............. 4351135 612001 Grainger et al ............. 5141319 712001 Wu at al. 712001 Anderson at al........... 62311.42 7/2001 Yang at al. 712001 Kunz 912001 Wright at al. 912001 Ding el al . ................ 42712 28 9/2001 Slepian 912001 Hosminy ct al. 10/2001 R.agheb at al, 1012001 Sydney et al. - ......... - 606/108 !012001 Barry et :d. 1012001 Whitbourne 10,12001 Kunz el al. 10,12001 Larson at al. 10!2001 Its" at al. 1112001 Caggtano et al, 11/2001 Ding et al . ................. 424/423 1/2002 K.atm3th et al. ............. 4241423 3,12002 Ding et al . ................ 42712.24 412002 Palasis at al . .............. 424/932 412002 Yang ......................... 623!1.42 512002 Alt ............................ 62311.15 6%2002 Kinsella et al .............. 514,449 514x19 612002 Scbafer 21203 Le Moat et it ............. 4241424 2J2003 Jayaraman ................. 427/2.24 412003 Pinchuk ct at .............. 5251240 7,12003 Wright at al ............... 62311.42 912003 Ding at al . ................ 62311 A3 612004 Llanos a al ................ 4281421 812004 Falotico at al ............. 62311.46 1012004 Wright et al . .............. 62311.42 1'2001 Roorda 1012001 Falotico at al......... 6041103.02 14`2001 Johnson 1012001 Yang at al. 1012001 Li et al. 1112001 Guruwaiya d al. 112002 Lary et at .............. 604/101.04 312002 Helruus et al, .............. 62311? 412002 Chudzik ct al, ............ 424/487 5,12002 Li at it. ..................... 424.424 612002 Shanlcy et al . ............ 623/1.16 612002 Ding et al. ................ 42712.24 612002 Shanley et al . ............ 62311.16 612002 Slrlmn ct at . .............. 62311.42 N2002 Ding at al, .................. 623112 712002 Palasis .................... 604196.01 7,12002 Furst ......................... 62311.16 ..... 62311.11 8,12002 Steinke ............ 812002 Levesque et al............ 4241423 9,12002 Mollison et al . ............ 5141291 9/2002 Schwartz et al. .......... 42712.15 912002 Das ........................... 62311.16 912002 Bajgar ct al ............... 62311.39 1112002 I-lanos ....................... 6041500 1212002 Hossainy at at. .........., 524/113 412003 Davila at it. ............. 6041265 11,12003 Falotico 312004 D ing at al . ................ 623/1.42 1212004 Falotico at al .............. 6041500 12/2004 Falotico et al .............. 6041500 112005 Falotico et al .............. 424/426 1/2005 Llanos at al ............... 623/1.46 2)2005 Falotico et at. ............. 6041500

Case 1:07-cv-00765-SLR

Document 1-2

Filed 11/27/2007

Page 6 of 25

US 7,300,662 B2
Page 5
2005!0106210 Al 200510187611 Al 200510208200 Al 200610088654 Al 2006+0089705 Al 5.12005 812005 9.72005 412006 412006 Ding at al . ................. 4241423 Ding at al . ................ 62311.15 Ding at it, ................ 42712.25 Ding or al, ................ 42712.21 Ding cl al . ................ 62311,15 1VO WO NO WO WO WO WO WO WO 01187372 Al 01187373 Al WO 01187376 Al 022126139 Al 02126271 Al 02/26280 Al 02/26281 Al 031015664 Al 03i057218 Al IU2001 1112001 1112001 412002 4/2002 412002 412002 2x2003 7/2003

FOREIGN PATENT DOCUMENTS
DE EP FP EP EP EP EP EP EP FP EP EP EP EP 19723723 Al 0 145 166 A2 0 177 330 A2 0 193 372 Al 0 221 570 A2 0 421 729 A2 0 540 290 A2 0 568 310 Al 0 604 022 Al 0 621 015 Al 0 623 354 Al 0 734 698 A2 0 712 615 Al 0 716 836 Al 0 800 801 At 0 734 721 Al 0 747 069 A2 0 761 251 Al 0 830 853 At 0 540 290 BI 0 815 803 At 0 850 651 A2 0 938 878 A3 0950386 B1 0 968 688 Al 0 633 032 BI 1 192 957 A2 1 588 726 Al 1 588 727 Al 0 566 807 Al 1 205 743 2 135 585 A 0 662 307 A2 660689 1457921 89/03232 Al WO9lil2779 Al WO 92115286 Al WO 94101056 At WO 94/21308 At WO 94121309 At WO 94124961 Al WO 96/00272 A[ WO 96126689 Al WO 96132907 Al WO 96134580 At 96141807 Al WO 97/25000 Al WO 97133534 Al 97135575 Al 98/08463 At WO 98113344 At WO 98!19628 At 98123244 Al WO 98123228 Al WO 98134669 At WO 98/36784 At WO 98147447 At WO 98156312 Al 00121584 At 00127455 Al WO 00127445 Al 00132255 At 00138754 At 01187342 A2 1211998 611985 411986 6/1986 511987 411991 1011992 11/1993 611994 1011994 1111994 311996 511996 611996 811996 1011996 1211996 311997 711997 111998 711998 711998 911999 10/1999 112000 212001 412002 1012005 1012005 411992 911970 911984 1211994 511979 211989 411989
911991

OTHER PUBLICATIONS
U.S. Appi. No. 071819,314, filed Jau, 9, 1992, ](Morris. U.S. Appl. No. 081424,884, filed Apr. 19, 1995, Helmus et at, U.S. Appl. No. 081526,273, filed Sep. 11, 1995, Ding. U.S. Appl. No. 081730,542, filed Oct. 11, 1996, Helutus. U,S. Appl. No. 091575,480, filed May 19, 2000, Kopia. U.S. Appl. No. 10/431,059, filed May 7, 2003, Falotico. Abraham, R. T., "Mammalian target of rapanycin : Irmmunosupressive drugs offer new insight into cell growth regulation," Progress in Inflammation Research , 2000, Switzerland. Alvarado, R. cl al., "Evaluation of Polymer -coated Balloon -expandable Stents in Bile Ducts," Radiology, 1989, 170, 975-978.

EP
EP FP EP EP EP

Badimon, J. J. et al., "Inhibitory Effects of Rapamycin on Intimal
Hypetplasia Afier PTCA," J ACC, Mar. 1998. Bailey at al., "Polymer Canting of Palma,-Schatz Stent Attenuates Vascular Spasm after Stent Placement," Circulation , 82;111-541

EP
EP EP EP EP

(1990).
Berk, B . C, at al., "Ph
EP
EP EP EP FR GB GB GB SU Su WO WO

WO
WO WO WO WO WO WO WO WO WO WO WO WO WO WO WO WO WO

WO
WO WO WO WO WO WO WO WO WO

911992 111994 911994 9/1994 11/1994 1/1996 911996 1011996 1111996 1211996 711997 911997 10!1997 3; 1998 411998 5/1998 611998 6/1998 8/1998 811998 10/1998 12/1998 412000 5/2000 512000 612000 712000 11/2001

Encyclopedia of Polymer Science and Engineering, vol. 7,
Fluococarbon Elastomers , p. 257.267 , Mar. 1989. Farb, A. ct it., "Vascular smooth muscle cell cytotoxicily and sustained inhibition of ncointirnal formation by fibroblast growth factor 2-saporin fusion protein," Cirr.. Res., 1997, 80, 542-550. Ferns, G. A. A. at at., "Inhibition of Neointimal Smooth Muscle Accumulation Alter Angioplasty by an Antibody to PDGF," Science, 1991, 253, 1129-1132.

Case 1:07-cv-00765-SLR

Document 1-2

Filed 11/27/2007

Page 7 of 25

US 7,300,662 B2
Page 6
Fischman, D. L. ct al., "A Randomized Comparison of CoronaryStent Placement and Balloon Angioplasty in the 'treatment of Coronary Arteryl)iseasc," N. Eng. J Afed., Aug. 25, 1994, 331(8), 496.501. Franklin, S. M. et al., "Pharmacologic prevention of restenosis alter coronary angioplasty: review of the randomized clinical trials," Coronary Artery Disease Mar. 1993, 4(3), 232-242. Fukuyama, J. et al., "Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet;" Ear, J. Pharrnacol., 1996, 318, 327-332. Gregory, C. R. et al., "Rapamycin Inhibits Arterial intimal Thickening Caused by Both Alloiramune and Mechanical Injury," Transplmuation, Jun. 1993, 55(6), 1409-1418. Gregory, C. R. et al, "`treatment with Rapamycin and Mycophenolic Acid Reduces Arterial Intimal Thickening Produced by Mechanical Injury and Allows Eudolhclial Replacement," Transplantation, Mar. 15, 1995, 59(5), 655-661.
Guyton, J. R. et al, "Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin;" Circ. Res., 1980, 46, 625-634.

Hansson, G. R. et al., "Interferon=! Inhibits Arterial Stenosis After Injury," Circa, 1991, 84, 1266-1272. Ilashemolhosseini, S. et al., "ILapnmycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin Di mRNA and Protein Stability," J Diol Client, Jun. 5, 1998, 273, 14424-14429. Jonasson, J. ct al., "Cyclosporin A inhibits smooth muscle prolif_ cration in the vascular response to injury," Pror.. Natl., Acad. SN., 1988, 85, 2303-2306. Kuhnc, M, et al., "Microbial Conversion of Rapamycin," Enzyme and Microbial Tech nobs,, 1997, 21, 405.412. Lange, R. A. MD ct al., "Restenosis Alter Coronary Balloon Angioplasty," Anna, Rev, Afed., 1991, 42, 127-132. Liu, M. W. et al., "Trapidil in Preventing Rcstcnosis After Balloon Angioplasty in the Atherosclerotic Rabbit," Circ., 1990, 81, 10891093, Liu, M. W., NID et al., "Restenosis After Coronary Angioplasty Potential Biologic Determinants and Role of Intimal I lyperplasia," Circularion, 1989, 79, 1374-1387. Lundergan, C. F. ct al., "Peptide inhibition of Myointimal Prolit cration by Angiopeptin, a Somatostatia Analogue," JACC, May 1991, 17(6), 1328-136B. Majesky, M. W. et al, "heparin regulates smooth muscle S phase entry in the injured rat carotid artery," Circ. Res., 19S7.61, 296-300. Mars, S. Q. et it., "Map-vrsycin-FKBP Irtribiis Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells," Circ. Res., 1995, 76, 412417. Nemecek, G. M. et ,it., "Terbinafinc Inhibits the Milogenic Response to Platelet-Derived Growth Factor in Vitro and Neoinimal Proliferation in Vivo," J. PharmacoL E.ip. Thera., 1989, 248, 1167-1174. Okada, T. et al., "Localized Release of Perivascitlar llep tnn Inhibits Intimal Proliferation alter Endothelial Injury without Systemic Anlicoagulalion," Aleurosurgery, 1989, 25, 892-899. Poon, M. ct al., "Rapamycin Inhibits Vascular Smooth Muscle Cell Migration," J Clin hivesr., Nov. 1996, 98(10), 2277-2283, Popma, J. J. et al., "Clinical trials of restenosis after coronary angioplasty," Circulation, Sep. 1991, 84(3), 1426-1436. Powell, J. S. et al., "Inhibitors of Angiotensin-Converting Enzyme Prevent Myuintimal Proliferation After Vascular Injury," Science, 1989, 245, 186-188. Rcnsing, B. J, ct al., Coronary restenosis elimination with a sirolimus eluting steni, European Heart Journal, 2001, 22, 21252130. Rodeck, C. et al., "Methods fur the Transcmical Collection of Fetal Cells During the First Trimester of Pregnancy," Prnnratal Diagnosis, 1995, 15, 935-942. Serruys, P. W. el at., "A comparison of balloon-expandible-stem implantation with balloon angioplasty in patients with coronary artery disease," N Engl J Afed, Aug. 25, 1994; 331(8), 489-495. Serruys, P. NV. ct al., "Evaluation of kclanscrin in the prevention of restenosis after percutancous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial," Circulation. Oct. 1993; 88(4 N 1), 1588-1601.

Serruys, P. NV. ct it., "Heparin-coated Palmaz-Schntz stents in human coronary arteries. Early outcome of the Senescent-11 Pilot Study," Circnlatfon, Feb. 1, 1996; 93(3), 412422. Siekierka, J. J., "Probing T -Cell Signal Transduction Pathways with the Immunosupressive Drugs, FK-506 and Rapamycin," Inrmunologic Research, 1994, 13, 110-116. Sigwan, et al., "Intravascular Stenos to Prevent Occlusion and Rcstcnosis After Transluminal Angioplasty," N. EngL J Afcd., Mar. 19, 1987, 316, 701-706. Simons, M. et al., "Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo," Nature, 1992, 359, 67-70, Snow, A. D. et a1., "Heparin modulates the composition of the extracellular matrix, domain surrounding arterial smooth muscle cells," Ant. J Parhol., 1990, 137, 313-330. Sollott, S. J. et al., "Thxol Inhibits Neoicttimal Smooth MUSCIe Cell Accumulation after Angioplasty in the Rat," J. Ulm Invest., 1995, 95, 1869-1876. van Der Giessen, et al, "Self-expandable Mesh Stents: an Expcrimental Study Comparing Polymer Coated and Uncoated Wallstent Stents in the Coronary Circulation of Pigs," Circulation 1990, 82(suppl. 111):111-542. van Der Giessen, W. J, ct al, "Coronary stenting with polymercoated and uncoated self-expanding endoprosthescs in pigs ' Coron. Art. Disease 1992; 3, 631-640. Vasey, C. G. ul a., "Clinical Cardiology: Stress Echo and Coronary Flow", , Circulation, Oct. 1989, 80(4) Supplement 11, 11-66. Verwcire, E. et al., "Evaluation of Fluorinated Polymers As Coronary Stent Coating," Jonu·ual of tfarerials Science: %farerials in medicine, Apr. 2000. Weinberger, J. et al, "Intracoronary irradiation: dose respoase for the prevention of restenosis in swine," her. J. Rad. One. Biol. PGys., 1996, 36, 767-775. Preliminary Amendment in ILS, Appl. No. 071258,189, May 22, 1989. Trial Transcript from Nov. 6, 2000 ai 185-90 and 235-36 (Attorney's opening remarks regarding '984 patent).
Trial Transcript from Nov. 7, 2000 at 274-301, 307-315, 320-28 and 332 (Cordis expert testimony regarding the Palrnaz-Schntz scent); 370-379, 490-496 (J. Palmaz testimony regarding the PalmazSchatz dent, the '984 patent and the connected z-stent art).

Trial Transcript from Nov. 8, 2000 at 547-63, 657-63, 674.722, 782-85 (Cordis expert testimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art). Trial Transcript from Nov. 9, 2000 at 819-23, 921 (Cordis expert testimony regarding lhe'984 patent); 926.941 . (R, Croce testimony re Palmaz-Schatz scent); 1033-1053. (It, Schatz testimony). Trial Transcript from Nov. 13, 2000 at 1086-1134, (R. Schatz testimony); 1275.1305 (Cordis expert testimony regarding the '984 patent). Trial T=script from Nov. 14, 2000 at 1390-140.7, 1448-1454, 1486-1500 (Cordis expert testimony regarding the '984 patent). Trial Transcript from Nov. 15, 2000 at 1686-87, 1724-42, 1828-34, 1850-54, 1887-92 (AVE expert testimony regarding the '984 patent). Trial Transcript from Nov. 16, 2000 at 2077-198 (AVE expert testimony regarding the alleged obviousness of the '984 patent). Trial Transcript from Nov. 17, 2000 at 2331-34 (jury instructions as to the meaning of the limitations of the claims of the '984 patent). Trial Transcript from Nov. 20, 2000 al 244148, 2499.2500, 254650, 2552.56 (Attorney's closing arguments regarding the '984 patent),
Trial Transcript from Nov. 21, 2000 at 2592-94 (reading of jury verdict).

Trial Transcript from Dec, 18, 2000 at 2750.95 (Cordis expert testimony regarding the Palmaz -Schatz stcnt during the damages phase). Trial Transcript from Dec, 20, 2000 at 3421-88 (AVE expert testimony regarding the Palmaz-Schatz stent during the damages phase). Jury verdict, dated Nov. 21, 2000. District Court decisions on post-trial motions (194 F. Supp. 2d 323). Court of Appeal for the Federal Circuit decision (339 Fad 1352).

Case 1:07-cv-00765-SLR

Document 1-2

Filed 11/27/2007

Page 8 of 25

US 7,300,662 B2
Page 7
Trial Transcript from Mau. 4, 2005 at 133-135, 171-173 and 192-96 (Attorney's opening remarks reguding '984 validity). Trial Transcript from Max. 7, 2005 at 275.31 1 (Cordis expert testimony regarding the Patmaz- Schatz stent); 342-46, 353-59, 416-425 Q. Palmaz testimony regarding the Palmaz-Schatz stem, the '984 patent and the connected z-stent art); 430-449, 452-58, 462492 (R. Croce testimony regarding the Palmaz-Schatz stent); 500-507 (Cordis expert testimony regading the '984 patent). Trial Transcript from Mar. 8, 2005 at 609 (Cordis expert testimony regarding the ' 984 patent ), 628-73, 724.740, 773, 801-839 (Cordis expert testimony regarding the '984 patent, the prior art and the Palmaz-Schatz stmt). Trial Transcript from Mar. 9, 2005 at 93649,968-69 (Cordis expert testimony regarding the '984 patent , the prior art and the PalniaazSchatz stent). Trial Transcript from Mar. 10, 2005 at 1427.74, 178-1509, 1514-23 (AVE expert t estimony regarding the alleged obviousness of the '984 patent); 1566.93 (AVE expert testimony regarding PalmazSchatz stmt); 163449 (R. Schatz testimony). Trial Transcript from Mar. It, 2005 at 184647, 1891-1900, 1919 (Attorneys' closingarguments regarding ' 984 obviousness). Trial Transcript from Mar, 14, 2005 at 1964-67 (reading of jury verdict). Jury verdict dated Mar. 14, 2005. Medtronic Vascular Inc.'s Opening Brief in Support of Its Motion for Judgment As A Infringement Ctaim dated Apr. 19, 2005. Medtronic Vascular Inc.'s Opening Brief in Support of Its Motion for a New Trial dated Apr. 19, 2005. D.I. 1407, Cordis' Combined Answering Brief In Opposition to AVE's Motion for JyIOL on Infringement of the Palmaz '762 and Schatz '984 Patents and Its Motion for a New Trial tilled May 5, 2005. D.I. 1414, Medtronic Vascular Inc.'s Combined Reply Brief In Support of Its Motion for Judgment as a Matter of Law on Cordis Corp.'s Patent Infringement Claims and Its Motion for a New'frial dated May 19, 2005. Trial Transcript from Feb. 8, 2001 at 372412, 449.469 (B. Tobor testimony regarding the prosecution of the '417, '984 and '332 patents); 510-13 (J. Milnamow testimony regarding the prosecution of the '332 patent); 558-604 (J. Paltin az testimony regarding the prosecution of the '417, '984 and '332 patents and the prior ail), Trial Transcript from Feb. 9, 2001 at 63745, 662-672, 682-85 (J. Palmaz testimony regarding the prior art); 699-742 (R. Schatz testimony); 769-770, 790.95 (Cordis exper testimony regarding prior art). D.I. 1067, Medtronic AVE, Inc.'s Pnst-Trial Brier Relating to the Unenforccability of the '762 and '984 Patents Due to Inequitable Conduct. D.I. 1077, Cordis' Combined Answering Brief in Opposition to AVE's BSC's Post-Hering Briefs on Alleged Inequitable Conduct Concerning the '762, '984 and '332 Patents. D.I. 1089, Reply Brief In Support of Medtronic AVE, Int.'s Contention that the '762 ,and '984 Patents :are Unenforceable Due to Inequitable Conduct dated May 7, 2001. C.A. No. 00-886-SLR, Answer and Counterclaims of Def, Medtronic AVE, Inc. To First Amended Complaint of Plaintiff Cordis Corp. BSC's Opening Post-Trial Brief in Support of Its Defcnse That the Patents in Suit Are Unenforceable, dated Mar. 16, 2001. Reply Brief in Support of BSC's Defense That the Patents in Suit Are Unenforceable, dated May 7, 2001. Court's Decision on allegations of inequitable conduct (194 R Supp. 2d 323) Mar. 28, 2002. Trial -Transcript from Nov. 21, 2000 at 155-57 nod 180-84 (Attorncys' opening remarks regarding '332 patent). Trial Truascript from Nov. 27, 2000 at 227-51, 260-300 (Cordis expert testimony regarding the Palmy..-Schatz scent); 343-60, 36367, 424-33 (J. Patmaz testimony regarding the Palmaz -Schatz stcnt and the '332 patent). Trial Transcript from Nov. 28, 2000 at 649-71. Trial Transcript from Nov. 29, 2000 at 791.816, 859-870, 953-62 (Cordis expert testimony regarding the '332 patent and the PalmazSchatz stent). Trial Transcript from Nov. 30, 2000 at 1018 (Cordis expert testimony rcguding the '332 patent); 1062-80, 1108-1I l l (R. Cracc testimony regarding the Palm'tz-Schatz stent); 1169-70, 1205-17, 1236.45 (Cordis expert testimony regarding the '332 patent). Trial Transcript from Dec. 1, 2000 at 1352.54 (Cordis expert testimony regarding the '332 patent); 1364-1442 (R. Schatz testimony); 1493.1508, 1552.69 (BSC expert testimony regarding the '332 patent and the Palmaz-Scham.. scent). Trial Transcript from Dec. 4, 2000 at 1602-12, 1638-51, 1713-14, 1730.61, 1811-14, 1823-36 (BSC expert testimony regarding the alleged obviousness of the '332 patent, the prior art and the Palmaz-Schal'z stent). Trial Transcript from Dec. 6, 2000 at 2318-27, 2342-58 (BSC expert testimony regarding the '332 patent).
Trial Transcript from Dec. 7, 2000 at 2549-52 (Cordis expert testimony regarding the '332 patent); 2575.2579, 2591-92, 263031, 2649, 2669-71, 2684-85, 2688, 2708-10, 2725.27 (Attorney closing argument regarding '332 portent); 2742-46 Q'wy instructions as to the meaning of the limitations to the claims of the '332 patent).

Trial Transcript from Dec. 11, 2000 at 2817. 72 (reading of jttiy verdict). Jury verdict, dated Dec. 11, 2000. D.I. 699, Motion by Defcndant BSC and Scimed Life Systems, Inc. For Summary Judgment of Invalidity of U.S. Patent No. 5,902,332 dated Apr. 4, 2000. D.I.896, Order Denying Motion for Summary.ludgment of Invalidity and Unenforceability of Claims 1, 3, and 5 of the U.S. Patent No. 5,902,332 Denying (699-11 Motion for Summary Judgment of Invalidity of U.S. Patent No. 5,902,332 dated Oct. 12, 2000. Wright el al., Percutaneous Endovascular Stent: An Experimental Study (Abstract), RSNA Meeting (Nov. 28, 1984). Hearing Transcript from Feb. 10, 1998 at 122-32, 146-80 (Attorneys' opening remarks regarding '417 patent); 180-312 (R. Schatz testimony) [Portions of "This Transcript Have Been Removed As Confidential]. licaring Transcript from Feb. 1 1, 1998 at 427-575, 577.651 (Cordis expert testimony regarding the '417 patent, the prior art and the Palmaz-Schatz stmt). Hearing Transcript frorrn Feb. 13, 1998 :d 1121-1261 (Guidant expert testimony regarding, the alleged obviousness of the '417 patent, the prior art and the Palmaz-Schatz stent). [Portions of This Transcript Have Been Removed As Confidential]. Order by J. Robinson denying Cordis' Motion for a Preliminary Injunction Against ACS dated Jug. 17, 1998. ACS, Int.'s and C,uidant Corp.'s Opening Brief in Support ofThcir Motion for Summary Judgment of Invalidity of U.S. Patent No. 5,102,417 dated Aug. 27, 1998. Plaintiffs' Answering Brief in Opposition to ACS' and BSC' Motion for Summary Judgment on Obviousness dated Sep. 24, 1998. Order &acd Mar. 31, 2000, Schatz Deposition Testimony; May 15, 1996: 79-83,89-92,105-107 and 153-161. Schatz Deposition Testimony; May 16, 1996: 555.564, 569-572, Schatz Deposition Testimony; Jan. 18, 1998: 67.73, 108-110. Schatz Deposition Testimony; Jul. 14, 1998; 59-77, 108-112, 119123. Schatz Deposition Testimony, Jul. 12, 1999: 88-91, 132-135, 144149, 218.223, 231-242. Schatz Deposition Testimony; Jul. 13, 1999: 251-334, 339.345, 374-416. Schatz Deposition Testimony; Jul. 14, 1999: 454-550. Schatz Deposition Testimony; Jul. 15, 1999: 560.614. Schatz Deposition Testimony; Dec, 2, 1999: 906-911, 928-942, 945-963, 976-978, 1029-1034, 1038-1042. Palmaz Deposition Testimony, Nov. 5, 1991: 160-172. Palmaz Deposition Testimony, Feb. 5, 1995: 710.727. Patmaz Deposition Testimony, Jul. 16, 1998: 55-56; 81-82. Palmaz Deposition Testimony, Jul. 28, 1999: 560-568, 570-579. Palmaz Depositioo 'T'estimony, Jul. 29, 1999; 778.785. Palmaz Deposition Testimony, Aug. 31, 1999: 1403-1452. Palmaz Deposition Testimony, Sep. 2, 1999: 1953-1960.

Case 1:07-cv-00765-SLR

Document 1-2

Filed 11/27/2007

Page 9 of 25

US 7,300,662 B2
Pape 8
Palmaz Deposition Testimony, Oct. 14, 1999: 2201-9209; 22752342; 2371-2411. Palmaz Deposition Testimony, Oct. 15, 1999: 2424-2497; 25082589. Palmaz Deposition Testimony, Oct. 16, 1999: 2853-2860. Tobor Deposition Testimony, Jun. 17, 1999: 837-958. Tobor Deposition Testimony, Jun. 18, 1999: 1095-1184. Tabor Deposition Testimony, Dec. 1, 1999: 1217-1371. Tobor Deposition Testimony, Dec. 2, 1999: 1398-1414; 1444-1508; 1532-1548. Tobor Deposition Testimony, Dec, 3, 1999: 1652-1653; 1662-1672; 1683-1694. Kula Deposition Testimony, Apr. 20, 1999: 268.169. Kula Deposition Testimony, Nov. 16, 1999: 660.675; 680-694; 748-755; 774-821. Kula Deposition Testimony, Nov. 18, 1999; 176-223. Expert Report of Dr. Rodney S. Badger an Behalf of Medtronic AVE, Inc. (Jan. 31, 2000). Expert Report of Dr. Joseph Bonn on Behalf of Medtronic AVE, inc. (Jan. 31, 2000). Deposition of Dr. Joseph Bonn dated Mar. 14, 2000. Rebuttal Expert Report of Nigel Buller, B.Sc., M.D., F.R.C,P. (Mar. 2000). Second Supplemental Rebuttal Expert Report ofNigel Buller, B.Sc., M.B., F.R.C.P. (Aug, 17, 2004). Rebuttal Expert Report of John M. Collins, PH.D. (Feb. 2000). Expert Report of David C. Cumberland, M.D. (Jan. 24, 2000), Expert Report of John T. Goolkasian (Feb. 2000). Deposition of Richard R. Heuser, M.D. (Sep. 7, 2004). Deposition of Henry R. Pichler (Sep. 10, 2004). Deposition of Ronald J, Solar (Mar, 22, 2000). Deposition of Ronald J. Solar (.Mar. 23, 2000), Deposition of Ronald J. Solar (Apr. 12, 2000). Export Report of Dr. Arina Van Breda on Behalf of Medtronic AVE, Inc. (Jan. 31, 2000). Deposition of Anna Van Breda (Mar. 24, 2000). Deposition of Arina Van Breda (Aug. 21, 2004). Expert Report of John F. Witherspoon (Jan. 24, 2000). Supplemental Expert Report of Jahn F. Witherspoon (Oct. 27, 2000). Deposition of John F. Witherspoon (Mar. 8, 2000). Palmaz et al., Attictc; Normal and Stenotic Rcnal Arteries: Experimental Balloon Expandable Intraluminnl Scenting, Radiology, Sep. 1987. (AVE 84). Julio C. Palmaz, Article: "Expandable vascular endoprosthesis." (AVE 132). Duprat ct. al., Artiele: Flexible Balloon-Expandable Stent for Small Vessels Dupmt et. al. Radiology, vol. 162, pp. 276-278,1987. (AVE 134). Coons et, al., Article: "Large-Bore, Long Biliauy Endoprosthesis (Biliary Steals) for Improved Drainage," Radiology, vol. 148, pp. 89-94, 1983. (AVE 143). Honickman el it., Article: "Malposilioned Biliary Endoprosthesis, Technical Developments And Instrumentation," vol. 144, No. 2., 1982. (AVE 144). Harries-Jones, cl al., Article: "Repositioning of Biliary Endoprosthesis with Gruntzig Balloon Catheters," AJR, vol. 138, pp. 771-772, 1982. (AVE 153). Charnsangavej ct al., Article "Stenosis of the Vena Cava: Preliminary Assessment of Treatment with Expandable Metallic Stents," Radiology, vol. 161, pp. 295-298, 1986. (AVE 359). Article "Tracheobronchial Tree: Expandable Metallic Stems Used in Experimental and Clinical Applications," Radiology, vol. 158, pp. 309-32, 1986. (AVE 364). T. Yoshioka, ct al., AIR Article: "Self-Expanding Endovascular Graft: An Experimental Study in Dolts", vul. 151, pp. 673.676, 1983. (AVE 438). Article: "Expandable Intraluminal Vascular Graft: A Feasibility Study," Surgery, vol. 99, pp. 199205, 1986. (AVE 461). Lawrence et al., Article: "Percutaneous Endovescular Graft: Experimental Evaluation." Radiology, vol. 163, pp. 357-360, 1987. (AVE 671). Palmaz ct al., Article: Expandable Intraluminal Graft: A Preliminary Study, Nov. 17-22, 1985, Radiology, vol. 156, pp. 73-77, 1985. (AVE 1224). Fallone ct al., "Llastic Characteristics of the Self-Expanding Metallie Stents;" Investigative Radiology, vol. 23, pp, 370-376, 1988. (AVE 1953). Palmaz Paper Entitled "Research Project Expandable Vascular Fntloprosthcsis" May 18, 1983, Rousseau, et al., Publication: "Percutaneous Vascular Stcnt: Experimental Studios & Preliminary Clinical Results in Peripheral Arterial Diseases," in Inter. Angio, vol. 6, 153-161, 1987. (AVE 3301). Rousseau , et al., Publication: "Self-Expanding Endavascular Prostcsis: An Experimental Study," Radiology, vol. 164, pp. 709714, 1987. (AVE 3303). Wallace, et al., Article: "Tracheobronchial Tree: Expandable Metallic Steals Used in Experimental and Clinical Applications," Radiology, vol. 58, pp. 309-312, 1986, (DBX 2938). Palmaz et al., Article: "Expandable Intraluminal Graf; A Preliminary Study," Radiology, vol. 156, pp. 73-77 (DBX 4595). Program for the 12th Annual Course on Diagnostic Angiogaphy and Interventional Radiology Mar. 23-26, 1987 sponsored by The Society of Cardiovascular and Interventional Radiology (DBX 6235). Preliminary Motion for Judgment rc Woltr claims 1 , 2-S. 10, 15 and 19 (DBX6759). Palmaz Declaration (DBX 7069). Letter from C:alemd to Dr. Palmaz dated Jul. 5, 1988 with attached document entitled: "Segmented, balloon-expandable stens." (DBX 7160). Duprat et al., Article: "Flexible Balloon-Expandable Stent For Small Vessels," Radiology, vol. 168, pp. 276-278, 1987 (PX 82). Drawing Sent to Bodic on Mar. 17, 1986 (PX 374). Letter from Dr. Palmaz. to R. Bowman enclosing a model of the [cxible coronary graft dated Mar. 17, 1986 (PX 337). Lab Notebook pages dated Jul. 30, 1987 from Rodney Wolff (COR 185596-597)(PX62[A). Charnsangavej, el al., Article: "Sleoosis of The Vena Cava Prelimlmnary Assessment of Treatment with expandable Metallic Stems," Radiology, vol. 161, No. 2, pp. 295-298 with attached photographs, 1986. (AP[ 72). J. Palmaz: The Current Status of Vascular Prostheses, published by SCIR in the Twelfth Annual Course on Diagnostic Angiogaphy And lntervcntional Radiology Mar. 23-26, 1987. (API 73). Amendment in Response to Office Action of Oct. 18, 1988 in re: Application of Julio Palmaz SrN 174,246. (API 152). Article: Wallace, c1 al., Tracheobronchial Tree: Expandable Metallic Steals Used in Experimental and Clinical Applications Work In Progress, Radiology, val. 158, pp. 309.312. (API 295). Reply of Senior Party Schatz To Patentee Wolffs Opposition To The Belated Motion For Judgment Of Applicant Schatz With Regard To Wolff Claims 1, 2-8,10, It, 13-17, And 19 (COR IW50.455)(API 310). Brief Of Senior Party Schatz At Final Hearing (API 313).

Letter from Ron Sickles to Ben Tobor dated Feb. 10, 1988 (Exhibit 42).
Letter from R.O. Sickles to Mike Tallow dated May 12, I988 (Exhibit 43). Letter from R. 0. Sickles to Richard Schatz dated Jun. 2, 1988 (Exhibit 44). Letter from Richar